The Hepatitis C Virus in Children

Unfortunately not enough is known about children with Hepatitis C because researchers and physicians have a difficult time tracking down children who suffer from this terrible infection.  There are two reasons for this. One is that children are less likely to show symptoms if they do have it and the second reason is that few of them are infected. Based on the way that people become infected with the Hepatitis C virus, also known as HCV, which is by blood-to-blood contact, this is not a surprise.  Children are not drug users, do not engage in unsafe sex nor are they as likely to be on dialysis or have blood transfusions.

Before changes in 1992, that improved blood testing making it more sensitive, and lowering infection risks to one in one hundred thousand, transfusions and maternal transfer were the ways that children were infected.  Its believed that a quarter of a million American children have Hepatitis C. The biggest issue here is that most of them remain untreated because no one knows they have the infection. Even the ones who have passed into the chronic stage only rarely show symptoms. If they do it may be that they are overly tired or even have some stomach pain that can't be easily defined.  But a doctor is unlikely to conclude from those that testing should be done for HCV.

Some studies have been conducted to try and understand how the Hepatitis C virus is passed to children and how their bodies deal with it. So far studies are inconclusive. They show that during heart surgeries there is more of a chance for a child to be infected by blood transfusion. But there is an equal chance of the child's body flushing the infection out, as there is that the child will remain infected. With adults there is a twenty five percent chance of having a spontaneous viral clearance.

Studies of children who have become infected by transmission from their mothers seem to pose as many questions as they answer.  For one thing it's not clear when the baby becomes infected. Researchers are not certain if it's in the womb or during the actual birth. They do know that it is not during breastfeeding, which is safe as long as the mother's nipples do not crack or bleed. Serum levels in these children are high for a short time and then seem to return to normal. But a liver biopsy will show that they have chronic hepatitis.

When treatment of children with Hepatitis C is begun in the acute stage its very successful. It appears that if only interferon is used in treatment, not in combination with anything, then the success rate is as high as seventy percent. But even these results pose questions for researchers. They do not know if it's the size of the dose, the smaller subject or a result of being able to track the disease's beginnings. Hopefully continued studies will conclude the best way to treat HCV in children.

Hepatitis news on the Web

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Sciences jumps on hepatitis C dataCBS News
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Lagonian.com -Barron's (blog)
all 63 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge
Scientists establish HCV infection in liver-like cells derived from iPSCsNews-Medical.net

all 5 news articles »

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
FDA removes hold on Idenix hep C drug targetMass High Tech
NASDAQ -Sacramento Bee
all 31 news articles »

HP awards Meg Whitman $16.5 million pay package - San Francisco Chronicle

HP awards Meg Whitman $16.5 million pay package
San Francisco Chronicle
Gilead's shares rose 11 percent on news a hepatitis C drug showed positive results in clinical trials. Gilead Sciences, the Foster City drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in ...

and more »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
Vertex Falls as analyst cuts sales estimates on hepatitis C pillBoston Globe
LocalizedUSA
all 15 news articles »

Prosecutor says doctor in hepatitis C outbreak is faking disabilities. - Las Vegas Review - Journal

Washington Examiner

Prosecutor says doctor in hepatitis C outbreak is faking disabilities.
Las Vegas Review - Journal
Desai, 62, is challenging state medical experts who found him competent to stand trial on criminal charges in the 2007 hepatitis C outbreak. » Buy this photo By Jeff German Dr. Dipak Desai, the physician at the center of the hepatitis C outbreak, ...
Judge: Dipak Desai competent to stand trial in hepatitis caseLas Vegas Sun
Desai found competent to stand trialLas Vegas Review-Journal
Ex-doc ruled fit for trial in Vegas hep C caseWashington Examiner

all 15 news articles »

researchers identify peptide that inhibits replication of hepatitis C - UC Los Angeles

researchers identify peptide that inhibits replication of hepatitis C
UC Los Angeles
By Kim Irwin February 02, 2012 Category: Health Sciences, Research Researchers from UCLA's Jonsson Comprehensive Cancer Center have identified a cell-permeable peptide that inhibits a hepatitis C virus protein and blocks the viral replication that can ...

and more »

March trial for Desai may be postponed again - Las Vegas Review - Journal

March trial for Desai may be postponed again
Las Vegas Review - Journal
Buy this photo By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas
Ex-doc ruled fit for trial in Vegas hepatitis-C caseMyNews3

all 5 news articles »

Vertex posts 4Q profit on growing Incivek sales - CBS News

Vertex posts 4Q profit on growing Incivek sales
CBS News
Drugmaker Vertex Pharmaceuticals Inc. said Thursday it turned a profit in the fourth quarter on sales of its hepatitis C pill Incivek, which was approved in May. Vertex reported a profit of $158.6 million, or 74 cents per share.
Curing Diseases Makes For a Bad Business ModelDailyFinance
Vertex roiled by fickle marketBizjournals.com
Vertex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking Alpha
Zacks.com
all 21 news articles »

Stem Cells May Further Hepatitis C Research - U.S. News & World Report

Stem Cells May Further Hepatitis C Research
U.S. News & World Report
31 (HealthDay News) -- Using stem cells to create liver-like cells for laboratory research may advance efforts to find out why people respond differently to hepatitis C infection, scientists say. It's not clear why some people are resistant to ...

and more »


Google News